soul trial oral semaglutide cardiovascular outcomes trial results (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine SOUL (Semaglutide cardiOvascular oUtcomes triaL)
Pay in 4 interest-free payments of $5.85 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Live Spec
SOUL (Semaglutide cardiOvascular oUtcomes triaL) in individuals with Download Scientific Diagram Forecasting Trial Milestones: A Predictive Analysis for Early Termination of the SOUL Study Diabetes Therapy Springer Nature Link soul trial oral semaglutide cardiovascular outcomes 2024 nejm results Long term kidney outcomes of semaglutide in obesity and cardiovascular disease Oral semaglutide is the first oral GLP 1 RA proven to reduce MACE in high risk T2DM patients, extending cardiovascular protection beyond injectable formulations. SOUL Trial: Oral Semaglutide & Cardiovascular Outcomes in T2DM
Store: finou-maps.com · Domain: finou-maps.com
